08:21 AM EDT, 10/20/2025 (MT Newswires) -- Adaptimmune Therapeutics ( ADAP ) said Monday that it will voluntarily delist its American depositary shares from the Nasdaq Capital Market and begin the process to deregister from US Securities and Exchange Commission reporting.

The company said it will file a Form 25 on Oct. 28, with Nasdaq trading expected to end after market close on Oct. 27.

The decision comes after Adaptimmuned received a Nasdaq notice giving the company until Dec. 1 to regain compliance with the $1 minimum bid price rule, which it is unlikely to meet, the company said.

The company said shares are expected to move to the OTC Pink Market, but continued trading is not guaranteed.

Adaptimmune said the move will help cut costs and regulatory burdens as it works to maximize remaining asset value.